Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

BACKGROUND: Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy of daclizumab in patients with relapsing-remitting multiple sclerosis (RRMS). We report...

Descripción completa

Detalles Bibliográficos
Autores principales: Gold, Ralf, Radue, Ernst-Wilhelm, Giovannoni, Gavin, Selmaj, Krzysztof, Havrdova, Eva, Stefoski, Dusan, Sprenger, Till, Montalban, Xavier, Cohan, Stanley, Umans, Kimberly, Greenberg, Steven J., Ozen, Gulden, Elkins, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962457/
https://www.ncbi.nlm.nih.gov/pubmed/27461166
http://dx.doi.org/10.1186/s12883-016-0635-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962457/
https://www.ncbi.nlm.nih.gov/pubmed/27461166
http://dx.doi.org/10.1186/s12883-016-0635-y

Ejemplares similares